PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
A61K 39/21, C07K 7/04

A1

(11) International Publication Number: WO 92/05800

(43) International Publication Date: 16 April 1992 (16.04.92)

(21) International Application Number: PCT/SE91/00641

(22) International Filing Date: 25 September 1991 (25.09.91)

(30) Priority data:
589,422 27 September 1990 (27.09.90) US

(71) Applicant: SYNTELLO VACCINE DEVELOPMENT KB [SE/SE]; Vasa Sjukhus Pav. 14, S-411 33 Göteborg (SE).

(72) Inventors: VAHLNE, Anders ; Igelkottsstigen 14A, S-430 80 Hovås (SE). SVENNERHOLM, Bo ; Jakobsdalgatan 48, S-412 69 Göteborg (SE). RYMO, Lars ; Hällekullavägen 17, S-430 80 Hovås (SE). JEANSSON, Stig ; Föreningsgatan 33, S-411 27 Göteborg (SE). HORAL, Peter ; Orangerigatan 21B, S-412 66 Göteborg (SE).

(74) Agents: ROTH, Michel et al.; Göteborgs Patentbyrå AB, Box 5005, S-402 21 Göteborg (SE).

(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU+,TD (OAPI patent), TG (OAPI patent).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PEPTIDES FOR USE IN VACCINATION AND INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS

(57) Abstract

In accordance with the present invention, novel peptides corresponding to epitopes of human immunodeficiency virus-1 gp120 protein and analogs and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against human immunodeficiency virus infection and in production of polyclonal and monoclonal antibodies. The peptides are selected from those with aminoacid coordinates 151-176, 192-218, 205-230.

+ See back of page

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CS	Czechoslovakia
DE	Germany
DK	Denmark
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GN	Guinea
GR	Greece
HU	Hungary
IT	Italy
JP	Japan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
LI	Liechtenstein
LK	Sri Lanka
LU	Luxembourg
MC	Monaco
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
NL	Netherlands
NO	Norway
PL	Poland
RO	Romania
SD	Sudan
SE	Sweden
SN	Senegal
SU+	Soviet Union
TD	Chad
TG	Togo
US	United States of America

Description

Peptides For Use in Vaccination and Induction of Neutralizing Antibodies Against Human Immunodeficiency Virus

Background of the Invention

The present invention relates to peptides suitable for use in vaccination against AIDS.

The human immunodeficiency virus (HIV) is responsible for the disease that has come to be known as acquired immune deficiency syndrome (AIDS). Although initially recognized in 1981, no cure has yet been found for this inevitably fatal disease. HIV is spread by a variety of means such as sexual contact, infected blood or blood products and perinatally. Due to the complexity of HIV infection and the paucity of effective therapies, eradication of AIDS will most likely occur by preventing new infections rather than curing those persons already infected. To this end a great deal of effort has been expended in developing methods for detecting and preventing infection. Diagnostic procedures have been developed for identifying infected persons, blood and other biological products.

Like most viruses, HIV often elicits the production of neutralizing antibodies, unlike many other viruses and other infectious agents for which infection leads to protective immunity, however, HIV specific antibodies are insufficient to halt the progression of the disease. Therefore, in the case of HIV, a vaccine that elicits the immunity of natural infection could prove to be ineffective. In fact, vaccines prepared from the HIV protein gp160 appear to provide little immunity to HIV infection although they elicit neutralizing antibodies. The failure to produce an effective anti-HIV vaccine has led to the prediction

that an effective vaccine will not be available until the end of the 1990's.

The HIV genome has been well characterized. Its approximately 10 kb encodes sequences that contain regulatory segments for HIV replication as well as the gag, pol and env genes coding for the core proteins, the reverse transcriptase-protease-endonuclease, and the internal and external envelope glycoproteins respectively.

The HIV env gene encodes the intracellular glycoprotein, gp160, which is normally processed by proteolytic cleavage to form gp120, the external viral glycoprotein, and gp41, the viral transmembrane glycoprotein. The gp120 remains associated with HIV virions by virtue of noncovalent interactions with gp41. These noncovalent interactions are weak, consequently most of the gp120 is released from cells and virions in a soluble form.

Previous studies have shown that the proteins encoded by the gag and especially the env regions of the HIV-1 genome are immunogenic since antibodies to the products of the gag and env genes are found in the sera of HIV infected, AIDS and ARC ("AIDS Related Condition") patients.

It has previously been shown that some antibodies obtained from sera of AIDS and ARC patients, as well as asymptomatic individuals infected with the virus are specific to gp120 and gp160. Occasionally these antibodies are neutralizing. The envelope glycoproteins are the HIV-1 antigen most consistently recognized by antibodies in AIDS and ARC patient sera. Allan et al., "Major Glycoprotein Antigens that Induce Antibodies in AIDS Patients are Encoded by HTLV-III", Science, 228:1091-1094 (1985); and Barin et al., "Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients", Science, 228:1094-1096 (1985). In addition, antibodies in

patient sera also recognize epitopes of the viral core proteins encoded by the gag gene.

Immunologically important HIV-1 antigens for use in diagnosis and as potential vaccine compositions have been prepared by cloning portions of the HIV-1 genome in various expression systems such as bacteria, yeast or vaccinia. Cabradilla et al., "Serodiagnosis of Antibodies to the Human AIDS Retrovirus With a Bacterially Synthesized env Polypeptide", Biotechnology, 4:128-133 (1986); and Chang et al., "Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) With an Immunoassay Employing a Recombinant *Escherichia coli* - Derived Viral Antigenic Peptide", Biotechnology, 3:905-909 (1985). HIV-1 antigens produced by recombinant DNA methods, however, must still be exhaustively purified to avoid adverse reactions upon vaccination and false positive reactions in ELISA assays due to any antibody reactivity to antigens of the expression system which may contaminate the HIV-1 antigen preparation. Also, denaturation of HIV-1 antigens during purification may destroy important antigen activity. Preparation of proteins from intact viruses can also result in contamination by intact virus.

Several publications have presented data showing immunologic reactivity of selected synthetic peptides corresponding to antigenic proteins of HIV-1. In one study, a peptide having the amino acid sequence Tyr-Asp-Arg-Pro-Glu-Gly-Ile-Glu-Glu-Glu-Gly-Gly-Glu-Arg-Asp-Arg-Asp-Arg-Ser-Gly-Cys which corresponds to amino acid residues 735-752 of HIV-1 was synthesized. Kennedy et al., "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", Science, 231:1556-1559 (1986). This peptide, derived from a portion of gp41, was used to immunize rabbits in an attempt to elicit a neutralizing antibody response to HIV-1. Furthermore, several sera from AIDS patients

known to contain anti-gp41 antibodies were weakly reactive with this peptide, thus indicating that this peptide contains at least one epitope recognized, to some extent, by antibodies to native gp160/gp41. However, this peptide has not been shown to elicit neutralizing antibodies in mammals other than rabbits nor has it been suggested for use as a human vaccine.

Summary of the Invention

In accordance with the present invention, novel peptides corresponding to epitopes of HIV-1 gp120 protein and analogues and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against HIV infection, induction of a heightened immune response to HIV and in production of polyclonal and monoclonal antibodies.

Detailed Description of the Invention

The present invention provides peptides which have been found to elicit production of HIV neutralizing antibodies by primate subjects. The peptides correspond to regions of the gp120 protein with coordinates as defined by Kennedy et al., "Antiserum to a Synthetic Peptide Recognizes the HTLV-III Envelope Glycoprotein", Science, 231:1556-1559 (1986). The peptides of the present invention are termed gp120-12 (amino acid coordinates 159-183), gp120-15 (amino acid coordinates 200-225), gp120-16 (amino acid coordinates 213-237) and gp120-19 (amino acid coordinates 255-276). Although peptide gp120-19 is similar to a peptide that has been described (Ho et al., Science, 239:1021-1023 (1988)), it has now been found that gp120-19 elicits neutralizing antibodies in primates. The peptides of the present invention can be used as immunogens in vaccine compositions and to elicit polyclonal or

monoclonal antibody production; particularly important are HIV neutralizing antibodies.

Proteins contain a number of antigenic determinants or epitopes which are the regions of the proteins comprising the recognition and binding sites for specific antibodies. In general, proteins contain between 5 to 10 epitopes, each of which contains a sequence of 6 to 8 amino acids. Epitopes can be either continuous, in which the 6 to 8 amino acids are present in linear sequence, or discontinuous, in which the amino acids that form the epitope are brought together by the three dimensional folding of the protein. Even though an epitope constitutes only a relatively few amino acids, its reactivity with an antibody may be influenced by the amino acids in the protein which surround the epitope.

Studies aimed at mapping antigenic sites or epitopes of proteins have been aided by the use of synthetic peptides corresponding to various regions of the proteins of interest. Lerner et al., in, The Biology of Immunological Disease: A Hospital Practice Book, (Dixon and Fisher, eds.) pp. 331-338 (1983); and Lerner, Adv. Immunol., 36:1 (1984). In addition to their usefulness in epitope mapping studies, synthetic peptides, if encompassing major antigenic determinants of a protein, have potential as vaccines and diagnostic reagents. Van Regenmortel, Ann. Inst. Pasteur/ Virol 137E:497-528 (1986); and Van Regenmortel, Laboratory Techniques in Biochemistry and Molecular Biology, Buroden and Van Knippenburg eds. Vol. 19, Synthetic Peptides as Antigens, Elsevier ISBN 0-444-80974-0 (1988).

Synthetic peptides have several advantages with regard to specific antibody production and reactivity. The exact sequence of the synthesized peptide can be selected from the amino acid sequence of the protein as determined by amino acid sequencing of the protein or

the predicted amino acid sequence determined from the DNA sequence encoding the protein. The use of specific synthetic peptides eliminates the need for the full-length protein in vaccination and the production of or assay for antibodies. Furthermore, the solid phase peptide synthetic techniques of Merrifield and coworkers allow for essentially unlimited quantities of the synthesized peptide of interest to be chemically produced. Erickson and Merrifield in The Proteins, 3rd Edit., Vol. 2, Academic Press, New York, Chapter 3 (1976). The availability of automated peptide synthesizers has further advanced such techniques.

Although a variety of criteria can be used to predict antigenic regions of proteins, peptides corresponding to such regions may not always be useful as vaccines. For example, antigenicity may be lost because the peptide is not in the proper spatial orientation to be recognized by antibodies which react with the protein. It has also been found that certain peptides derived from type C retroviruses and HIV act as immune-suppressive agents much as HIV itself. Cianciolo et al., J. Immunol., 124:2900-2905 (1980); and Cianciolo et al., Proc. Natl. Acad. Sci. USA, 230:453-455 (1985). Peptides such as these, which have an adverse effect on the patient, would not be suitable for use as vaccines.

Furthermore, as is particularly evident with HIV-1 and HIV-2, there is significant genetic variability within each of these two virus groups leading to many serotypes, or isolates, of the viruses. This has put a significant constraint on choosing a region of a protein from which to derive a peptide for use in formulating immunogens. However, certain immunodominant portions of HIV-1 and HIV-2 proteins have been found to be relatively invariant. Synthetic peptides may also be key to viral vaccines in that they may induce an immune response against common sequences

not normally immunogenic in the native molecule. These otherwise silent epitopes may be of broad protective specificity. Stevard et al., Immunol. Today, 8:51-58 (1987). Several experimental vaccines have been formulated with the aim of preventing infection in those people who are likely to be exposed to the virus. Berman et al., "Protection of Chimpanzees from Infection by HIV-1 After Vaccination With Recombinant Glycoprotein gp120 but not gp160", Nature, 345:622-625 (1990).

Synthetic peptides corresponding to regions of immunologically important proteins of HIV have now found immediate use in diagnostic methods for detection of HIV, as potential vaccines for HIV and for the production of polyclonal and monoclonal antibodies.

A number of neutralization epitopes on gp120 have been found and defined by several investigators, for an overview see Bolognesi, AIDS, 3(suppl 1):S111-s118 (1989). In his overview Bolognesi refers to four different virus neutralization epitopes with the following amino acid coordinates: 254-274, 303-337, 458-484 and 491-523. The peptide with amino acid coordinates 254-274 was used to immunize rabbits and the resulting antiserum was found to neutralize HIV-1 as described above.

The peptides encompassed by the invention comprise amino acid sequences each containing at least one continuous (linear) epitope that elicits production of HIV specific antibodies in the immunized host.

The invention thus encompasses immunogenic peptides corresponding to regions of HIV gp120 protein encoded by the envelope gene of HIV-1 HTLV III-B described by Muesing et al., "Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus", Nature, 313:450-458 (1985). The nucleotide sequence is given in Genbank Release 63 under the name HIVPV22. The invention further

encompasses functionally equivalent variants of the peptides which do not significantly affect the immunogenic properties of the peptides. For instance, conservative substitution of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogues are within the scope of the invention.

Homologs are peptides which have conservatively substituted amino acid residues. Amino acids which can be conservatively substituted for one another include but are not limited to: glycine/alanine; valine/isoleucine/leucine; asparagine/glutamine; aspartic acid/glutamic acid; serine/threonine; lysine/arginine; and phenylalanine/tyrosine. Homologous peptides are considered to be within the scope of the invention if they are recognized by antibodies which recognize the peptides designated gp120-12, gp120-15, gp120-16 and gp120-19 the sequences of which are shown below. Further, all homologous peptides corresponding to the peptides of the present invention but derived from different HIV isolates are also encompassed by the scope of this invention.

Analogues are defined as peptides which are functionally equivalent to the peptides of the present invention but which contain certain non-naturally occurring or modified amino acid residues. Additionally, polymers of one or more of the peptides, and peptide analogues or homologs are within the scope of the invention. Also within the scope of this invention are peptides of fewer amino acid residues than gp120-12, gp120-15, gp120-16 and gp120-19, respectively, but which encompass one or more immunogenic epitopes present in any one of the peptides and thus retain the immunogenic properties of the base peptide.

The peptides were synthesized by known solid phase peptide synthesis techniques. Merrifield and Barany,

The Peptides: Analysis, Synthesis, Biology, Vol. 1, Gross and Meinenhofer, eds., Academic Press, New York, Chap. 1 (1980). The synthesis also allows for one or more amino acids not corresponding to the original protein sequence to be added to the amino or carboxyl terminus of the peptide. Such extra amino acids are useful for coupling the peptides to another peptide, to a large carrier protein or to a solid support. Amino acids that are useful for these purposes include but are not limited to tyrosine, lysine, glutamic acid, aspartic acid, cysteine and derivatives thereof. Additional protein modification techniques may be used, e.g., NH_2-acetylation or COOH-terminal amidation, to provide additional means for coupling the peptides to another protein or peptide molecule or to a support. Procedures for coupling peptides to each other, carrier proteins and solid supports are well known in the art. Peptides containing the above-mentioned extra amino acid residues either carboxy or amino terminally, uncoupled or coupled to a carrier or solid support are consequently within the scope of the invention. Reference to the peptides of the present invention encompasses all of the embodiments discussed herein.

An alternative method of vaccine production is to use molecular biology techniques to produce a fusion protein containing one or more of the peptides of the present invention and a highly immunogenic protein. For instance, fusion proteins containing the antigen of interest and the B subunit of cholera toxin have been shown to induce an immune response to the antigen of interest. Sanchez et al., "Recombinant System For Overexpression of Cholera Toxin B Subunit In Vibrio cholerae as a Basis for Vaccine Development", Proc. Natl. Acad. Sci. USA, 86:481-485 (1989).

The novel peptide sequences are set forth below. The amino acid residues are derived from the nucleotide sequence previously described by Muesing et al.,

"Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus", Nature, 313:450-458 (1985). It is preferred that the peptides possess an amido group at their carboxy termini rather than a carboxyl group. The carboxy terminus can also be a carboxyl group as well as a moiety described below.

gp120-12
X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y-Z

gp120-15
X-Leu-Thr-Ser-Cys-Asn-Thr-Ser-Val-Ile-Thr-Gln-Ala-Cys-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Y-Z

gp120-16
X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y-Z

gp120-19
X-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-Glu-Glu-Y-Z

wherein X is either a hydrogen atom of the amino terminal NH_2 group of the peptide or an additional amino acid being selected to facilitate coupling of the peptide to a carrier; Y is absent or Cys; and Z is the carboxyl group of the carboxy terminal amino acid or an amido group. The amino acid abbreviations used are defined in Table 2.

The peptides are useful as vaccines to protect against future infection by HIV or to heighten the immune response to HIV in subjects already infected by HIV. Although any human subject could be vaccinated with the peptides, the most suitable subjects are people at risk for HIV infection. Such subjects include but are not limited to homosexuals,

prostitutes, intravenous drug users and those in the medical professions who have contact with patients or biological samples. The invention also provides monoclonal and polyclonal antibodies which specifically recognize the peptides. The invention further provides antibodies which neutralize HIV.

In the preferred embodiment of the present invention, the peptides are formulated into compositions for use as immunogens. These immunogens can be used as vaccines in mammals including humans or to elicit production of polyclonal and monoclonal antibodies in animals. For formulation of such compositions, an immunogenically effective amount of at least one of the peptides is admixed with a physiologically acceptable carrier suitable for administration to mammals including humans. The peptides may be covalently attached to each other, to other peptides, to a protein carrier or to other carriers, incorporated into liposomes or other such vesicles, and/or mixed with an adjuvant or adsorbent as is known in the vaccine art. For instance, the peptide or peptides can be mixed with immunostimulating complexes as described by Takahashi et al., "Induction of CD8+ Cytotoxic T Cells by Immunization With Purified HIV-1 Envelope Protein and ISCOMS", Nature, 344:873-875 (1990). Alternatively, the peptides are uncoupled and merely admixed with a physiologically acceptable carrier such as normal saline or a buffering compound suitable for administration to mammals including humans.

As with all immunogenic compositions for eliciting antibodies, the immunogenically effective amounts of the peptides of the invention must be determined empirically. Factors to be considered include the immunogenicity of the native peptide, whether or not the peptide will be complexed with or covalently attached to an adjuvant or carrier protein or other carrier and route of administration for the

composition, i.e. intravenous, intramuscular, subcutaneous, etc., and the number of immunizing doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.

The invention is further illustrated by the following specific examples which are not intended in any way to limit the scope of the invention.

Example 1

Peptide Synthesis

An Applied Biosystems peptide-synthesizer Model 430A, was utilized for the synthesis of the peptides of the present invention. Each synthesis used a p-methylbenzylhydrylamine solid phase support resin (Peptides International, Louisville, KY). The peptides were synthesized according to the Users Manual for Peptide Synthesizer Model 430A, Applied Biosystems, 1986.

All amino acids for use in synthesis contained t-butylcarbonyl groups (t-Boc) protecting the α-NH_2 group and were obtained from Novabiochem AG, Switzerland. Amino acids with reactive side chain groups contained additional protective groups to prevent unwanted and undesirable side chain reactions. The individual protected amino acids used in synthesizing all of the peptides are set forth in Table 1.

Table 1

Amino Acids Used in Peptides Synthesis

Boc-Ala-OH
Boc-Arg (Tos)-OH
Boc-Asn-OH
Boc-Asp (Obzl)-OH
Boc-Cys (Pmeobzl)-Oh
Boc-Glu (Obzl)-OH
Boc-Gln-OH
Boc-Gly-OH
Boc-His-(Tos)-OH
Boc-Ile-OH^1/2 H_2O
Boc-Leu-OH^H_2O
Boc-Lys (2-CI-Z)-OH (cryst.)
Boc-Met-OH
Boc-Phe-OH
Boc-Pro-OH
Boc-Ser (Bzl)-OH^DCHA
Boc-Thr (Bzl)-OH
Boc-Trp (Formyl)-OH
Boc-Tyr (2-Br-Z)-OH
Boc-Val-OH

Tos: Tosyl or p-Toluene sulfonic acid
Obzl = Benzyloxy
Pmeobzl = p-Methylbenzyloxy
2-CL-Z = Carbobenzoxy chloride
2-Br-Z = Carbobenzoxy bromide

After completion of a particular synthesis, the protecting groups were removed from the synthesized peptide and the peptide was cleaved from the solid support resin by treatment with Trifluoromethane Sulfonic Acid (TFMSA) according to the method described by Bergot et al., "Utility of Trifluoromethane Sulfonic Acid as a Cleavage Reagent in Solid Phase Peptide Synthesis", Applied Biosystems User Bulletin, Peptide Synthesizer, Issue No. 16, Sept. 2, 1986. The following is the detailed protocol used.

1. For 1 gram peptide-resin, 3 ml Thio-Anisol 1,2-Ethane-Dithiol (2:1) was added as scavenging agent and the mixture was incubated with continuous stirring for 10 min. at room temperature.

2. Trifluoracetic Acid (TFA), 10 ml, was added and stirred continuously for 10 min. at room temperature.

3. TFMSA, 1 ml, was added dropwise with forceful stirring and reacted for 25 min. at room temperature.

4. Following cleavage, the peptides were precipitated with and washed with anhydrous ether.

5. The precipitated and washed peptides were dissolved in a small volume of TFA (approximately 5ml).

6. The dissolved peptides were again precipitated and washed as above in step 4 and the precipitate was dried under a stream of N_2.

Prior to use in specific assays, the peptides can be further purified, if desired, by reverse phase high performance liquid chromatography (HPLC). A particularly suitable column for such purification is the reverse-phase Vydak® C-18 column using a water (TFA) - acetonitrile (TFA) gradient to elute the peptides. Forty peptides were synthesized having the amino acid sequences shown in Table 2.

TABLE 2

Peptide	Amino Acid Coordinates**	Amino Acid Sequence*
gp120-1	1-28	MRVKEKYQHLWRWGTMLGMLMIC
gp120-2	22-46	GMLMICSATEKLWVTVYYGVPVWK
gp120-3	40-64	GVPVWKEATTTLFCASDAKAYDTE
gp120-4	53-74	CASDAKAYDTEVHNVWATHAC
gp120-5	64-89	VHNVWATHACVPTDPNPQEVVLVNV
gp120-6	74-100	VPTDPNPQEVVLVNVTENFNMWKNDM
gp120-7	89-116	TENFNMWKNDMVEQMHEDIISLWDQSL
gp120-8	100-126	VEQMHEDIISLWDQSLKPCVKLTPLC
gp120-9	116-141	KPCVKLTPLCVSLKCTDLKNDTNTN
gp120-10	126-151	VSLKCTDLKNDTNTNSSSGRMIMEK
gp120-11	141-164	SSSGRMIMEKGEIKNCSFNISTS
gp120-12	151-176	GEIKNCSFNISTSIRGKVQKEYAFF
gp120-13	164-192	IRGKVQKEYAFFYKLDIIPIDNDTTSYT
gp120-14	176-205	YKLDIIPIDNDTTSYTLTSCNTSVITQAC
gp120-15	192-218	LTSCNTSVITQACPKVSFEPIPIHYC
gp120-18	205-230	PKVSFEPIPIHYCAPAGFAILKCNN
gp120-17	218-247	APAGFAILKCNNKTFNGTGPCTNVSTVQC
gp120-18	230-257	KTFNGTGPCTNVSTVQCTHGIRPVVST
gp120-19	247-269	THGIRPVVSTQLLLNGSLAEEE
gp120-20	257-282	QLLLNGSLAEEEVVIRSANFTDNAK
gp120-21	269-295	VVIRSANFTDNAKTIIVQLNQSVEIN
gp120-22	282-306	TIIVQLNQSVEINCTRPNNNTRKS
gp120-23	295-320	CTRPNNNTRKSIRIQRGPGRAFVTI
gp120-24	306-326	IRIQRGPGRAFVTIGKIGNMRQAH
gp120-25	320-343	GKIGNMRQAHKNISRAKWNNTLK
gp120-26	326-353	KNISRAKWNNTLKQIDSKLREQF
gp120-27	343-366	QIDSKLREQFGNNKTIIFKQSSG
gp120-28	353-377	GNNKTIIFKQSSGGDPEIVTHSFN
gp120-29	366-389	GDPEIVTHSFNCGGEFFYCNSTQ

TABLE 2

Peptide	Amino Acid Coordinates**	Amino Acid Sequence*
gp120-30	377-400	CGGEFFYCNSTQLFNSTWFNSTW
gp120-31	389-409	LFNSTWFNSTWSTEGSNNTE
gp120-32	400-417	STEGSNNTEGSDTITLP
gp120-33	409-429	GSDTITLPCRIKQFINMWQE
gp120-34	417-444	CRIKQFINMWQEVGKAMYAPPISGQIR
gp120-35	429-453	VGKAMYAPPISGQIRCSSNITGLL
gp120-36	444-466	CSSNITGLLLTRDGGNNNNESE
gp120-37	453-476	LTRDGGNNNNESEIFRPGGGDMR
gp120-38	466-488	IFRPGGGDMRDNWRSELYKYKV
gp120-39	476-497	DNWRSELYKYKVVKIEPLGVA
gp120-40	488-511	VKIEPLGVAPTKAKRRVVQREKR

*Amino acid abbreviations

Alanine	Ala	A	Leucine	Leu	L
Arginine	Arg	R	Lysine	Lys	K
Asparagine	Asn	N	Methionine	Met	M
Aspartic acid	Asp	D	Phenylalanine	Phe	F
Cysteine	Cys	C	Proline	Pro	P
Glutamine	Gln	Q	Serine	Ser	S
Glutamic acid	Glu	E	Threonine	Thr	T
Glycine	Gly	G	Tryptophan	Trp	W
Histidine	His	H	Tyrosine	Tyr	Y
Isoleucine	Ile	I	Valine	Val	V

** As previously described by Muesing et al.

Example 2

Cells and Virus Stocks

All neutralization tests were performed using H-9 cells and HTLV-111B virus (originating from R.C. Gallo and supplied by Dr. William Hall, North Shore Hospital, Manhasset, New York). H-9 cells (designated H9 NY) were maintained in RPMI Medium (Gibco) supplemented with 20% fetal calf serum (FCS), penicillin/streptomycin (PEN/STREP 50 µg/ml each and without any fungicides). Cells were subcultured at a dilution of 1:3 every 4 days.

Cells were scraped from the plates and pelleted by centrifugation at 325 x g. Pelleted cells were resuspended in 1 ml of stock virus previously diluted 1/10 and allowed to adsorb for 60 min at 37°C with frequent stirring. After adsorption of the virus, the cells were recentrifuged and resuspended in 10 ml of RPMI with 20% FCS and polybrene (2 µg/ml) (giving a final concentration of $5x10^5$ cells/ml) and incubated at 37°C in 5% CO_2.

Infected cells were shown to be detectable at 4-5 days post-infection (p.i.) by monitoring syncytia formation, positive cells in immunoflourescence and p-24 production (assayed by the Abbott p-24 antigen test). The peak of HIV production was seen 10 - 15 days p.i. at which time virus was collected. After low speed centrifugation to remove debris, supernatants containing virus collected from infected cells were frozen in stocks at -90°C. One virus stock with endpoint titer of 40,000 50% tissue culture infective doses ($TCID_{50}$) was used throughout the studies (referred to as NT3-NT19).

Example 3

Preparation of Peptides for Immunization

Peptides according to the present invention were covalently coupled to ovalbumin grade V (Sigma, St. Louis, MO, USA) at an approximate 10:1 (peptide:ovalbumin) molar ratio using N-succinimidyl

3-(2-pyridyldithio) propionate (SPDP), (Pharmacia, Uppsala, Sweden) as bifunctional linker according to the manufacturer's instructions (Pharmacia) i.e. briefly as follows.

Ovalbumin was dissolved in coupling buffer (0.2M NaH_2PO_4, pH 8.5). The dissolved ovalbumin was then run through a Sephadex G-25M column (Pharmacia, Sweden), using the same buffer. Protein concentration was measured at 280 nm and the recovery was determined. SPDP was dissolved in 99.5% ethanol to a final concentration of 40 mM. SPDP was then added dropwise to the ovalbumin solution under stirring. The SPDP-ovalbumin mixture was then left at room temperature for approximately 30 minutes. The ovalbumin-SPDP conjugate was separated from unconjugated SPDP by running the mixture through a Sephadex G-25M column, using water as eluent. The degree of substitution for the ovalbumin-SPDP conjugate was determined after diluting 50 µl conjugate in 2 ml of water, by measuring the diluted conjugate at 280 nm and the diluted conjugate plus 100 µl Dithiothreitol (DTT) (Sigma) at 343 nm, in order to determine the amount to be added to the peptide solution.

Finally, the synthetic peptide to be coupled to the ovalbumin-SPDP conjugate was dissolved in 10% acetic acid to a final concentration of 1 mg/ml and a suitable amount of ovalbumin-SPDP conjugate (as determined by the substitution degree above) was added and allowed to stand overnight at room temperature.

Example 4

Immunization Protocols

Maccaca fascicularis were used to generate antibodies. Prior to the initial peptide injection a blood sample was drawn from the monkeys. This initial blood sample is termed "pre-immune" (Tables 3-6) and is used as an internal control and analyzed simultaneously with respective immuneserum.

The monkeys were injected with 100 μg peptide-SPDP-ovalbumin suspended in 0.5 ml phosphate buffered saline (PBS). The monkeys were immunized intramuscularly three times, three weeks apart. As adjuvant, 0.5 ml of Freund's complete adjuvant was used for all immunizations. Two weeks after the final immunization the monkeys were bled and pre-immune and hyperimmune sera were subject to neutralization assays as described in Example 5.

Example 5

HIV-1 Neutralization Assay

Sera containing antibodies that neutralize HTLV 111-B infectivity were detected by their ability to prevent HIV-1 syncytium formation, p-24 antigen production and decreased number of infected cells as determined by immunoflourescence markers, compared to control infections lacking peptide specific antisera. Stock virus, described in Example 2 was diluted to 100 $TCID_{50}$ and mixed with serial fourfold dilutions (1/5, 1/20, and 1/80) of complement-inactivated immunesera obtained from the monkeys immunized as described in Example 4. As a positive control, a guinea pig hyperimmune serum (referred to as MSV) with known HIV neutralizing titer of 1/40 - 1/160 was included in all experiments (kindly provided by Prof. B. Morein, Dept. Veterinary Virology, BMC, Uppsala, Sweden). After incubation for 60 min at 37°C or 16 hours at 4°C, the serum-virus mixture was added to $1x10^6$ H-9 cells and incubated for another 60 min at 37°C. Following incubation, the cells were washed once and placed in 24 well multidish plates with 2 ml of growth medium (RPMI, 10% FCS, 2 μg polybrene/ml) per well.

Cells were examined under the microscope (magnification x 200) for the presence of syncytia on days 5-12 p.i. Supernatants from infected cells were assayed for the presence of p-24 antigen according to the

manufacturer's instructions (Abbott ag test HIVAG-1®, Enzyme Immunoassay for the Detection of Human Immunodeficiency Virus Type I (HIV-1) Antigen(s) in Human Serum or Plasma) in tenfold serial dilutions (1/10 - 1/1,000) at 10 days p.i. The results are presented as absorbance values at 454 nm with higher absorbance values indicating higher protein concentration and hence HIV infection. Serial dilutions of the supernatants were made so as to detect p-24 concentrations in the most accurate range (< 2.0 absorbance units).

The number of infected cells were determined at the end of experiment (usually on day 15 p.i.) by acetone-fixation of cells on slides adopted for immuneflourescence (IF). An indirect IF test was used according to standard procedures described in Jeansson et al., "Elimination of Mycoplasmas from Cell Cultures Utilizing Hyperimmune Sera", Ex. Cell Res., 161:181-188 (1985), with 1/400 dilution hyperimmune sera from HIV-infected individuals and a fluorescein isothiocyanate (FITC) labeled antihuman IgG antibody (Bio-Merieux France) diluted 1/100. Tables 3-6 show the results obtained from screening of hyperimmune sera from monkeys immunized with peptides 1-40.

In Tables 3(A-D)-6 the p24 antigen content of the supernatants was analyzed by ELISA as described above. The relative amount of antigen positive cells is depicted as AG POS cells wherein the percentages are represented by:

- = 0%, + = >0-2%, ++ = 3-10% and +++ = 11-20% where the percentage interval indicates the number of antigen positive cells.

Table 3A (HIVNT3P1.XLS) depicts the results obtained with sera derived from monkeys immunized with peptides gp120-1 - gp120-10. The cells used were H9 NY and the virus used was HTLV-IIIB, Batch 18 described in Example 2. The incubation protocol was (virus plus serum) incubation at 37°C for one hour.

Table 3B (HIVNT4P1.XLS) depicts the results obtained with sera derived from monkeys immunized with peptides gp120-11 - gp120-20. The cells used were H9 NY and the virus used was HTLV-IIIB, Batch 18 described in Example 2. The incubation protocol was (virus plus serum) incubation at 37°C for one hour.

Table 3C (HIVNT5P1.XLS) depicts the results obtained with sera derived from monkeys immunized with peptides gp120-21 - gp120-30. The cells used were H9 NY, and the virus used was HTLV-IIIB, Batch 18 described in Example 2. The incubation protocol used was (virus plus serum) incubated at 37°C for one hour.

Table 3D (HIVNT6P1.XLS) depicts the results obtained with sera derived from monkeys immunized with peptides gp120-31 - gp120-40. The cells used were H9 NY and the virus used was HTLV-IIIB, Batch 18 described in Example 2. The incubation protocol was (virus plus serum) incubation at 37°C for one hour.

Table 4 (HIVTAB4.XLS) shows the results of the first retest of putative neutralizing antibodies as determined by the first test (Tables 3A-D). In each test the virus used was HITLV-IIIB, Batch 18 and the cells used were H9 NY. The First Retest results in rows 1-19 are the results of neutralization test number 5. The incubation protocol was incubation at 37°C for one hour. The First Retest results in rows 20-32 are the results of neutralization test number 7. The incubation protocol was incubation of at 37°C for one hour.

Table 5 (HIVTAB5.XLS) shows second, third and fourth retest results of the positive peptides. In each test the virus used was HTLV-IIIB Batch 18 and the cells used were H9 NY. The Second Retest results in rows 1-4 are the results of neutralization test number 7. The incubation protocol was incubation at 37°C for one hour. The Second Retest results in rows 5-13 are the results of naturalization test number 12. The Third Retest results shown in rows 14-16 are the results of neutralization

test number 12. The incubation protocol was incubation at 37°C for one hour. The Fourth Retest results in rows 17-39 are the results of neutralization test number 16. The incubation protocol was at 4°C for 16 hours. The Second Retest results in rows 40-53 are the result of neutralization test 19. The incubation protocol was cells plus virus at 4° for 16 hours.

Table 6 (HIVKOMBP.XLS) shows the neutralization assay results with combined hyperimmune sera. Note that the incubation of virus and cells was at 4°C for 16 hours.

The results depicted in Tables 3(A-D)-6 indicate that the peptides of the present invention elicit the production of HIV neutralizing antibodies in primate subjects. The use of the peptides in vaccination of human subjects is therefore applicable to prevent infection by HIV or to induce heightened immune response in subjects already infected by HIV.

TABLE 3A - ASSAYS OF ANTISERA TO PEPTIDES gp120-1 - gp120-10

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
1.	Pos control		> 2.0	1.176	0.158	+++
2.	Pos control		> 2.0	1.194	0.177	+++
3.	Pos control		> 2.0	> 2.0	0.464	+++
4.	Neg control		0.056	-	-	-
5.	guinea pig	1/10	0.178	0.066	0.063	-
6.	Pos control	1/40	0.71	0.118	0.06	++
7.	Antiserum	1/160	> 2.0	0.742	0.11	++
8.		1/320	> 2.0	0.484	0.093	+++
9.	preimmune		ND	ND	ND	ND
10.	gp120-1	1/5	0.715	0.108	0.054	++
11.		1/20	> 2.0	0.36	0.073	++
12.		1/80	> 2.0	0.57	0.093	++
13.	preimmune		> 2.0	0.437	0.081	++
14.	gp120-2	1/5	> 2.0	0.86	0.138	++
15.		1/20	> 2.0	0.486	0.093	+++
16.		1/80	> 2.0	0.257	0.083	+++
17.	preimmune		> 2.0	0.466	0.09	++
18.	gp120-3	1/5	> 2.0	0.367	0.079	++

TABLE 3A - ASSAYS OF ANTISERA TO PEPTIDES gp120-1 - gp120-10

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
19.		1/20	2.0	0.512	0.094	++
20.		1/80	> 2.0	0.724	0.113	++
21.	preimmune		> 2.0	0.536	0.094	++
22.	gp120-4	1/5	> 2.0	0.638	0.092	++
23.		1/20	> 2.0	0.448	0.082	++
24.		1/80	> 2.0	0.592	0.097	++
25.	preimmune		> 2.0	0.43	.082	++
26.	gp120-5	1/5	> 2.0	0.638	0.098	++
27.		1/20	> 2.0	0.737	0.11	++
28.		1/80	> 2.0	0.786	0.119	+++
29.	preimmune		> 2.0	0.822	0.125	++
30.	gp120-6	1/5	> 2.0	0.716	0.131	+++
31.		1/20	> 2.0	0.977	0.119	++
32.		1/80	> 2.0	0.861	0.124	++
33.	preimmune		> 2.0	0.719	0.116	++
34.	gp120-7	1/5	> 2.0	0.587	0.106	++
35.		1/20	> 2.0	0.45	0.092	++
36.		1/80	> 2.0	0.756	0.117	++
37.	preimmune		> 2.0	0.507	0.096	+++

TABLE 3A - ASSAYS OF ANTISERA TO PEPTIDES gp120-1 - gp120-10

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
38.	gp120-8	1/5	> 2.0	0.555	0.098	++
39.		1/20	> 2.0	0.59	0.103	++
40.		1/80	> 2.0	0.308	0.081	++
41.	preimmune		> 2.0	0.322	0.076	+++
42.	gp120-9	1/5	> 2.0	0.358	0.09	++
43.		1/20	> 2.0	0.403	0.082	+++
44.		1/80	> 2.0	0.612	0.102	+++
45.	preimmune		> 2.0	0.747	0.127	++
46.	gp120-10	1/5	> 2.0	0.3	0.074	++
47.		1/20	> 2.0	0.426	0.092	++
48.		1/80	> 2.0	0.442	0.083	++

TABLE 3B - ASSAYS OF ANTISERA TO PEPTIDES gp120-11 - gp120-20

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
1.	preimmune	1/5	> 2.0	0.882	0.149	++
2.	gp120-11	1/5	> 2.0	0.73	0.135	++
3.		1/20	> 2.0	1.73	0.299	++
4.		1/80	> 2.0	0.700	0.148	++
5.	preimmune	1/5	> 2.0	1.07	0.151	++
6.	gp120-12	1/5	0.157	0.07	0.076	+
7.		1/20	> 2.0	1.45	0.22	++
8.		1/80	> 2.0	1.37	0.221	++
9.	preimmune	1/5	> 2.0	0.58	0.107	++
10.	gp120-13	1/5	> 2.0	1.16	0.194	++
11.		1/20	1.816	0.37	0.095	++
12.		1/80	> 2.0	1.16	0.187	++
13.	preimmune	1/5	> 2.0	> 2.0	0.281	++
14.	gp120-14	1/5	> 2.0	0.81	0.142	++
15.		1/20	> 2.0	1.39	0.219	++
16.		1/80	> 2.0	0.83	0.156	++
17.	preimmune	1/5	> 2.0	1.13	0.192	++
18.	gp120-15	1/5	> 2.0	1.43	0.243	+++
19.		1/20	0.069	0.05	0.05	-

SUBSTITUTE SHEET

TABLE 3B - ASSAYS OF ANTISERA TO PEPTIDES gp120-11 - gp120-20

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
20.		1/80	> 2.0	0.57	0.104	++
21.	preimmune	1/5	> 2.0	1.78	0.303	++
22.	gp120-16	1/5	0.26	0.07	0.056	+
23.		1/20	0.067	0.06	0.054	-
24.		1/80	> 2.0	0.74	0.132	++
25.	preimmune	1/5	> 2.0	1.13	0.171	++
26.	gp120-17	1/5.	> 2.0	0.76	0.161	++
27.		1/20	> 2.0	1.56	0.285	++
28.		1/80	> 2.0	0.7	0.129	++
29.	preimmune	1/5	> 2.0	1.41	0.177	++
30.	gp120-18	1/5	> 2.0	> 2.0	0.339	++
31.		1/20	> 2.0	1.36	0.218	++
32.		1/80	> 2.0	1.26	0.199	++
33.	preimmune	1/5	> 2.0	0.39	0.097	++
34.	gp120-19	1/5	0.476	0.1	0.061	+
35.		1/20	1.048	0.18	0.068	+
36.		1/80	> 2.0	1.62	0.303	++
37.	preimmune	1/5	> 2.0	1.11	0.189	++

TABLE 3B - ASSAYS OF ANTISERA TO PEPTIDES gp120-11 - gp120-20

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS
			1/10	1/100	1/1000	
38.	gp120-20	1/5	> 2.0	1.19	0.182	+++
39.		1/20	> 2.0	1.47	0.054	++
40.		1/80	> 2.0	1.42	0.264	++

SUBSTITUTE SHEET

TABLE 3C - ASSAY OF ANTISERA TO PEPTIDES 21-30

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/10	1/100	1/1000		Day 5	Day 7
41.	pos control		> 2.0	0.65	0.09	++	12	72
42.	pos control		1.85	0.24	0.061	++	6	27
43.	neg control		0.4				0	0
44.	guinea pig	1/10	0.5	0.04	0.047	-	0	0
45.	pos control	1/40	0.05	0.04	0.04	-	1	0
46.	antiserum	1/160	0.04	0.05	0.043	+	1	3
47.		1/640	1.07	0.14	0.056	+	2	19
48.	preimmune	1/5	> 2.0	1.57	0.275		12	85
49.	gp120-21	1/5	> 2.0	0.4	0.075	++	3	28
50.		1/20	1	0.17	0.059		5	21
51.		1/80	> 2.0	0.48	0.089		7	72
52.	preimmune	1/5	> 2.0	1.1	0.182		3	ND
53.	gp120-22	1/5	> 2.0	1.48	0.221	++	2	75
54.		1/20	> 2.0	1.07	0.16		0	80
55.		1/80	> 2.0	0.63	0.087		5	90
56.	preimmune	1/5	> 2.0	0.4	0.083		4	52
57.	gp120-23	1/5	1.97	0.26	0.067	ND	0	20
58.		1/20	> 2.0	1.63	0.236		5	98

SUBSTITUTE SHEET

TABLE 3C - ASSAY OF ANTISERA TO PEPTIDES 21-30

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/10	1/100	1/1000		Day 5	Day 7
59.		1/80	> 2.0	0.35	0.084		5	>150
60.	preimmune	1/5	> 2.0	> 2.0	0.355		2	49
61.	gp120-24	1/5	1.95	0.29	0.067	+	0	3
62.		1/20	> 2.0	0.37	0.081		5	34
63.		1/80	1.87	0.24	0.069		3	48
64.	preimmune	1/5	> 2.0	0.83	0.145		0	91
65.	gp120-25	1/5	> 2.0	0.73	0.11	++	1	25
66.		1/20	1.63	0.23	0.062		0	15
67.		1/80	1.88	0.22	0.064		0	38
68.	preimmune	1/5	> 2.0	0.48	0.089		0	79
69.	gp120-26	1/5	> 2.0	0.62	0.101	++	3	91
70.		1/20	> 2.0	0.34	0.063		3	35
71.	gp120-26	1/80	1.27	0.19	0.061		0	21
72.	preimmune	1/5	> 2.0	0.66	0.11		2	52
73.	gp120-27	1/5	> 2.0	0.58	0.098	++	1	26
74.		1/20	> 2.0	0.65	0.099		6	49
75.		1/80	> 2.0	0.3	0.062		2	35
76.	preimmune	1/5	> 2.0	> 2.0	0.317		7	31

TABLE 3C - ASSAY OF ANTISERA TO PEPTIDES 21-30

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/10	1/100	1/1000		Day 5	Day 7
77.	gp120-28	1/5	> 2.0	0.39	0.078	++	2	22
78.		1/20	> 2.0	0.68	0.105		5	70
79.		1/80	0.99	0.15	0.05		3	>150
80.	preimmune	1/5	> 2.0	1.29	0.187		5	97
81.	gp120-29	1/5	> 2.0	0.55	0.096	++	3	112
82.		1/20	> 2.0	0.85	0.135		3	>150
83.		1/80	> 2.0	0.72	0.113		0	29
84.	preimmune	1/5	> 2.0	> 2.0	0.326		10	130
85.	gp120-30	1/5	> 2.0	0.27	0.073	+	3	38
86.		1/20	> 2.0	1.71	0.24		9	52
87.		1/80	> 2.0	0.44	0.082		6	ND

TABLE 3D - ASSAYS OF ANTISERA TO PEPTIDES 31-40

	PEPTIDE	Serum Dilution	P-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL
			1/10	1/100	1/1000		Day 6
88.	pos control		0.976	0.258	0.123		6
89.	pos control		1.836	0.656	0.185		11
90.	neg control						
91.	guinea pig	1/10	0.103	0.088	0.09		0
92.	pos control	1/40	0.104	0.087	0.093		0
93.	antiserum	1/160	0.749	0.29	0.1		4
94.		1/640	1.066	0.238	0.237		7
95.	preimmune	1/5	0.824				
96.	gp120-31	1/5	1.769	0.675	0.186		47
97.		1/20	1.124	0.302	0.111		22
98.		1/80	0.978	0.258	ND		24
99.	preimmune	1/5	0.883				
100.	gp120-32	1/5	1.163	0.258	ND		7
101.		1/20	1.482	0.311	ND		8
102.		1/80	0.996	0.263	ND		0
103.	preimmune	1/5	1.76				
104.	gp120-33	1/5	0.84	0.239	0.156		20
105.		1/20	1.282	0.333	0.144		16

TABLE 3D - ASSAYS OF ANTISERA TO PEPTIDES 31-40

	PEPTIDE	Serum Dilution	P-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL
			1/10	1/100	1/1000		Day 6
106.		1/80	0.76	0.207	ND		17
107.	preimmune	1/5	ND				
108.	gp120-34	1/5	0.293	0.134	0.12		18
109.		1/20	1.446	0.391	0.148		17
110.		1/80	0.42	0.15	ND		
111.	preimmune	1/5	ND				
112.	gp120-35	1/5	1.485	0.52	0.142		10
113.		1/20	1.778	0.873	0.194		26
114.		1/80	1.475	0.196	ND		
115.	preimmune	1/5	1.076				
116.	gp120-36	1/5	0.957	0.26	0.149		28
117.		1/20	1.44	0.448	0.119		16
118.		1/80	1.148	0.486	ND		
119.	preimmune	1/5	1.563				
120.	gp120-37	1/5	0.666	0.155	0.098		15
121.		1/20	1.143	0.33	0.129		12
122.		1/80	1.362	0.33	ND		
123.	preimmune	1/5	1.364				

TABLE 3D - ASSAYS OF ANTISERA TO PEPTIDES 31-40

	PEPTIDE	Serum Dilution	P-24 ANTIGEN (Supernatant DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL
			1/10	1/100	1/1000		Day 6
124.	gp120-38	1/5	1.386	0.59	0.114		11
125.		1/20	0.576	0.214	0.106		17
126.		1/80	1.23	0.329	ND		
127.	preimmune	1/5	1.854				
128.	gp120-39	1/5	1.376	0.495	0.182		28
129.		1/20	0.711	0.296	0.118		17
130.		1/80	0.929	0.237	ND		
131.	preimmune	1/5	ND				
132.	gp120-40	1/5	0.862	0.255	0.132		13
133.		1/20	0.989	0.273	0.143		10
134.		1/80	0.477	0.164	ND		

TABLE 4 - RETESTING OF HYPERIMMUNE SERA WITH THE CAPACITY TO NEUTRALIZE HIV

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/10	1/100	1/1000		Day 5	Day 7
First Retest								
1.	pos control		> 2.0	0.646	0.09	++	12	72
2.	pos control		1.853	0.244	0.061	++	6	27
3.	neg control		0.039				0	0
4.	guinea pig	1/10	0.051	0.04	0.047	-	0	0
5.	pos control	1/40	0.052	0.042	0.04	-	1	0
6.	antiserum	1/160	0.042	0.046	0.043	+	1	3
7.		1/640	1.067	0.144	0.056	+	2	19
8.	preimmune	1/5	2	1.326	0.172		10	112
9.	gp120-12	1/5	1.083	0.153	0.06	+	1	24
10.		1/20	2	1.487	0.171		7	175
11.		1/80	2	0.463	0.07		6	ND
12.	preimmune	1/5	2	1.991	0.237		2	64
13.	gp120-16	1/5	2	0.355	0.07	+	0	13
14.		1/20	0.741	0.103	0.048		0	11
15.		1/80	2	0.32	0.08		0	35
16.	preimmune	1/5	> 2.0	0.547	0.082		3	42
17.	gp120-19	1/5	0.141	0.062	0.053	+	0	6

TABLE 4 - RETESTING OF HYPERIMMUNE SERA WITH THE CAPACITY TO NEUTRALIZE HIV

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (DIL)			RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/10	1/100	1/1000		Day 5	Day 7
18.		1/20	1.134	0.164	0.054		0	26
19.		1/80	> 2.0	0.455	0.081		1	45
First Retest			**1/5**	**1/50**	**1/500**		**Day 7**	**Day 10**
20.	pos control		1.175	0.426	0.201		9	46
21.	pos control		1.529	0.401	0.161		32	167
22.	neg control							
23.	guinea pig	1/10	0.139	0.165	0.145	-	0	0
24.	pos control	1/40	0.211	0.159	0.168	-	1	0
25.	antiserum	1/160	0.961	0.299	0.163	++	9	26
26.		1/640	0.989	0.26	0.159	++	5	20
27.	gp120-24	1/5	1.067	0.245	0.166	++	4	34
28.		1/20	0.795	0.204	0.167	++	5	41
29.		1/80	0.433	0.167		-	15	80
30.	gp120-25	1/5	1.237	0.282	0.155	++	19	144
31.		1/20	1.312	0.373	0.187	++	42	116
32.		1/80	ND	ND	ND	-	ND	ND

TABLE 5 - RETESTING OF HYPERIMMUNE SERA WITH CAPACITY TO NEUTRALIZE HTLV-III

	PEPTIDE	SERUM DILUTION	p-24 ANTIGEN (Supernatant DIL)			*RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/5	1/50	1/500		Day 5	Day 7
Second Retest								
1.	gp120-16	1/5	ND	ND	ND		ND	ND
2.		1/5	1.924	1.062	0.282	++		
3.		1/20	0.365	0.172	0.145	-	2	5
4.		1/80	0.163	0.133		-	0	0
Second Retest			**1/10**	**1/100**	**1/1,000**			
5.	pos control		> 2.0	> 2.0	1.026	+++	320	
6.	pos control		> 2.0	> 2.0	0.639	+++	220	
7.	pos control		> 2.0	> 2.0	0.866	+++	290	
8.	pos control		> 2.0	> 2.0	0.881	+++		
9.	neg control		0.223			-		
10.	neg control		0.16			-		
11.	gp120-24	1/5	> 2.0	> 2.0	0.545	+++	112	
12.		1/20	> 2.0	> 2.0	0.819	+++	138	
13.		1/80	> 2.0	> 2.0		+++	230	
Third Retest								
14.	gp120-16	1/5	0.122	0.1	0.115	-	0	

TABLE 5 - RETESTING OF HYPERIMMUNE SERA WITH CAPACITY TO NEUTRALIZE HTLV-III

	PEPTIDE	SERUM DILUTION	p-24 ANTIGEN (Supernatant DIL)			*RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/5	1/50	1/500		Day 5	Day 7
15.		1/20	> 2.0	1.14	0.352	++	0	
16.		1/80	> 2.0	> 2.0		+++	210	
Fourth Retest								
17.	pos control		1.425	0.732	0.154	++	16	
18.	pos control		1.346	0.672	0.152	+++	16	
19.	pos control		1.431	0.845	0.182	+++	17	
20.	pos control		1.414	0.931	0.251			
21.	neg control		0.067			-		
22.	neg control		0.045			-		
23.	neg control		0.042			-		
24.	guinea pig	1/10	0.044	0.037	0.029		0	
25.	pos control	1/40	0.063	0.039	0.029		0	
26.	antiserum	1/160	0.036	0.035	0.055		0	
27.		1/640	0.556	0.072	0.034		1	
28.	gp120-12	1/8	0.072	0.043	0.046		0	
29.		1/32	0.169	0.054	0.047		0	
30.		1/128	> 2.0	1.124	0.241		19	
31.	gp120-16	1/8	0.043	0.045	0.049		0	

TABLE 5 - RETESTING OF HYPERIMMUNE SERA WITH CAPACITY TO NEUTRALIZE HTLV-III

	PEPTIDE	SERUM DILUTION	p-24 ANTIGEN (Supernatant DIL)			*RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/5	1/50	1/500		Day 5	Day 7
32.		1/32	0.052	0.043	0.048		0	
33.		1/128	1.54	0.903	0.014		4	
34.	gp120-19	1/8	0.105	0.043	0.042		0	
35.		1/32	0.358	0.08	0.045		5	
36.		1/128	> 2.0	0.944	0.205		25	
37.	gp120-24	1/8	> 2.0	0.885	0.155		2	
38.		1/32	> 2.0	1.174	0.293		15	
39.		1/128	1.158	0.858	0.213		11	
Second Retest			**1/5**	**1/50**	**1/500**		**Day 5**	**Day 7**
40.	pos control		0.916	0.166	0.099			74
41.	pos control		1.607	0.469	0.151			130
42.	pos control		> 2.0	0.943	0.203			123
43.	pos control		1.445	0.319	0.082			195
44.	neg control		0.145					
45.	neg control		0.328					
46.	guinea pig	1/10	0.09	0.111	0.075			0
47.	pos control	1/140	0.096	0.082	0.078			0
48.	antiserum	1/160	0.094	0.109	0.091			0

TABLE 5 - RETESTING OF HYPERIMMUNE SERA WITH CAPACITY TO NEUTRALIZE HTLV-III

	PEPTIDE	SERUM DILUTION	p-24 ANTIGEN (Supernatant DIL)			*RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL	
			1/5	1/50	1/500		Day 5	Day 7
49.		1/640	0.996	0.212	0.104			35
50.	preimmune	1/5	> 2.0	0.444	0.162			95
51.	gp120-15	1/5	0.155	0.094	0.111			ND
52.		1/20	0.152	0.109	0.158			4
53.		1/80	0.176	0.13	0.207			0

TABLE 6 - COMBINED NEUTRALIZATION EFFECTS OF SERA FROM MONKEYS

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			NT TITRE OF SERUM	RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL
			1/5	1/50	1/500			Day 6
1.	Pos control		1.4	0.7	0.154		++	16
2.	Pos control		1.3	0.7	0.152		+++	16
3.	Pos control		1.4	0.8	0.182			17
4.	Pos control		1.4	0.9	0.251			
5.	neg control		0.1				-	
6.	neg control		0				-	
7.	neg control		0				-	
8.	guinea pig	1/10	0	0	0.029			0
9.	pos control	1/40	0.1	0	0.029			0
10.	antiserum	1/160	0	0	0.055	160		0
11.		1/640	0.6	0.1	0.034			1
12.	Group I	1/8	0	0	0.038			1
13.	gp120.mix	1/32	0	0	0.041			0
14.	12+16+19+24	1/128	0.2	0.1	0.043	> 128	-	0
15.	Group II	1/8	0.1	0	0.046			0
16.	gp120.mix	1/32	0.1	0.1	0.046		-	0
17.	16+19	1/128	0.1	0.2	0.043	> 128	-	0

TABLE 6 - COMBINED NEUTRALIZATION EFFECTS OF SERA FROM MONKEYS

	PEPTIDE	Serum Dilution	p-24 ANTIGEN (Supernatant DIL)			NT TITRE OF SERUM	RELATIVE AMOUNT OF AG POS CELLS	NO. OF SYNCYTIA/WELL
			1/5	1/50	1/500			Day 6
18.	Group III	1/8	0	0	0.051			0
19.	gp120.mix	1/32	0.1	0.1	0.043		-	0
20.	16+24	1/128	1	0.3	0.065	128	++	1
21.	Group IV	1/8	0.2	0	0.044			2
22.	gp120.mix	1/32	0.1	0	0.045		-	1
23.	16+12	1/128	0.2	0.1	0.048	> 128	-	0
24.	gp120-12	1/8	0.1	0	0.046		-	0
25.		1/32	0.2	0.1	0.047	32	+	0
26.		1/128	> 3	1.1	0.241			19
27.	gp120-16	1/8	0	0	0.049			0
28.		1/32	0.1	0	0.048	32	-	0
29.		1/128	1.5	0.9	0.138		-	4
30.	gp120-19	1/8	0.1	0	0.042		-	0
31.		1/32	0.4	0.1	0.045	32	-	5
32.		1/128	> 3	0.9	0.205		++	25
33.	gp120-24	1/8	> 3	0.9	0.155	neg		2
34.		1/32	> 3	1.2	0.293			15
35.		1/128	1.2	0.9	0.213			11

Claims

1. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y-Z and analogues and homologs of said sequence.

2. The peptide according to claim 1 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

3. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe and analogues and homologs of said sequence.

4. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: X-Leu-Thr-Ser-Cys-Asn-Thr-Ser-Val-Ile-Thr-Gln-Ala-Cys-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Y-Z and analogues and homologs of said sequence.

5. The peptide according to claim 4 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent

or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

6. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: Leu-Thr-Ser-Cys-Asn-Thr-Ser-Val-Ile-Thr-Gln-Ala-Cys-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys and analogues and homologs of said sequence.

7. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y-Z and analogues and homologs of said peptide.

8. The peptide according to claim 7 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

9. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn and analogues and homologs of said peptide.

10. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence:

X-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-Glu-Glu-Y-Z and analogues and homologs of said sequence.

11. The peptide according to claim 10 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

12. A peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-Glu-Glu and analogues and homologs of said sequence.

13. A vaccine composition comprising an immunologically effective amount of a peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence: X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y-Z and analogues and homologs of said sequence and a physiologically acceptable carrier therefor.

14. The composition according to claim 13 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group

consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

15. A vaccine composition comprising an immunologically effective amount of a peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence:
X-Leu-Thr-Ser-Cys-Asn-Thr-Ser-Val-Ile-Thr-Gln-Ala-Cys-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Y-Z and analogues and homologs of said sequence and a physiologically acceptable carrier therefor.

16. The composition according to claim 15 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

17. A vaccine composition comprising an immunologically effective amount of a peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence:
X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y-Z and analogues and homologs thereof and a physiologically acceptable carrier therefor.

18. The composition according to claim 17 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent

or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

19. A vaccine composition comprising an immunologically effective amount of a peptide having at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequence:
X-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-Glu-Glu-Y-Z
and analogues and homologs of said sequence and a physiologically acceptable carrier therefor.

20. The composition according to claim 19 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

21. A vaccine composition comprising an immunologically effective amount of at least two peptides wherein each peptide has at least one epitope recognized by antibodies specific to human immunodeficiency virus, said epitope being within the amino acid sequences:
X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y-Z;

X-Leu-Thr-Ser-Cys-Asn-Thr-Ser-Val-Ile-Thr-Gln-Ala-Cys-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Y-Z;

X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y-Z; and

X-Thr-His-Gly-Ile-Arg-Pro-Val-Val-Ser-Thr-Gln-Leu-Leu-Leu-Asn-Gly-Ser-Leu-Ala-Glu-Glu-Glu-Y-Z

and analogues and homologs of said sequences and a physiologically acceptable carrier thereof.

22. The composition according to claim 21 wherein X is selected from the group consisting of a hydrogen atom of the amino terminal NH_2 group of the peptide and an additional amino acid selected to facilitate coupling of the peptide to a carrier; Y is absent or cysteine and Z is selected from the group consisting of the carboxyl group of the carboxy terminal amino acid and an amido group.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00641

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5: A 61 K 39/21, C 07 K 7/04

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
IPC5	A 61 K; C 07 K

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched[8]

SE,DK,FI,NO classes as above

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category *	Citation of Document,[11] with indication, where appropriate, of the relevant passages[12]	Relevant to Claim No.[13]
X	WO, A1, 8707616 (BIOGEN N.V ET AL.) 17 December 1987, see claims 1-6, fig. 1 and page 9, lines 26-33 --	1-3,13, 14,21-22
X	WO, A1, 8910416 (TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ET AL.) 2 November 1989, see claims 10-11 and pages 20-23 --	1-3,13, 14,21, 22
X,Y	Chemical Abstracts, volume 112, no. 23, 4 June 1990, (Columbus, Ohio, US), Neurath, A. R. et al.: "B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides ", see page 454, abstract 214787s, & J. Gen. virol. 1990, 71(1), 85- 95 --	1-22

* Special categories of cited documents:[10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
3rd March 1992	1992 -03- 05
International Searching Authority	**Signature of Authorized Officer**
SWEDISH PATENT OFFICE	Carl Olof Gustafsson

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	EP, A2, 0330359 (BIO-RAD LABORATIORIES, INC.) 30 August 1989, see page 5, peptide 55 --	1-3,10-14,19-22
X	WO, A1, 8602383 (INSTITUT PASTEUR) 24 April 1986, see page 26 - page 29; claims 8,15 --	1-3,10-14,19-22
X	Journal of Acquired Immune Deficiency Syndromes, Vol. 2, 1989 S Modrow et al.: "Use of Synthetic Oligopeptides in Identification and Characterization of Immunological Functions in the Amino Acid Sequence of the Envelope Protein of HiV-1", see page 21 - page 27 see Tables 1 and 2, peptides 170-181, 213-225 and 254-266	4-6,10-12,15, 16,19, 20
Y	--	1-22
X,Y	Ed. Dani bolognesi, "Hiv binding to the CD4 molecule: conformation dependence and binding inhibition studies", J.S. Mc Dougal et al., 1988, Human Retroviruses, Cancer, and AIDS:, see pages 269-281, Table 2, peptides 41, 42 and 43 --	1-22
X	Tibtech, Vol. 8, 1990 Dani P. Bolognesi: "Approaches to HIV vaccine design", see page 40 - page 45	10-12, 19-20
Y	--	1-22
X	AIDS, Vol. 3, 1989 D P Bolognesi: "HIV antibodies and caccine design", see page 111 - page 118 page 112 and page 115	10-12, 19-20
Y	--	21,22
X	Science, Vol. 239, February 1988 D D Ho et al.: "Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody Neutralization", see page 1021 - page 1023	10-12, 19,20
Y	--	21,22

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	WO, A1, 8905820 (ARCH DEVELOPMENT CORPORATION) 29 June 1989, see the whole document --	10-12, 19-20, 21,22
Y	US, A, 4943628 (J I ROSEN ET AL.) 24 July 1990, see in particular table 1, peptides C42-C44 --	10-12, 19-22
Y	Chemical Abstracts, volume 111, no. 7, 14 August 1989, (Columbus, Ohio, US), Palker, Thomas J et al.: "Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes ", see page 553, abstract 55349m, & J. Immunol. 1989, 142(10), 3612-3619 --	21,22
P,X	WO, A2, 9115512 (GENENTECH, INC.) 17 October 1991, see claim 1, peptides b,c,d and e, fig 1A-1 och 2, peptides T7-T14b and page 39 --	1-20
P,X	EP, A1, 0459779 (CEDARS-SINAI MEDICAL CENTER) 4 December 1991, see Table III, peptidesC2-1-C2-7 --	4-12,15-20
P,X	WO, A1, 9104045 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 4 April 1991, see Table 2 (page 49) peptides 13-117, pages 10-12 and claims --	4-9,15-18

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE [1]

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers....., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING [2]

This International Searching Authority found multiple inventions in this international application as follows:

see next sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additonal fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional seach fees.

The general problem underlying the invention is not novel-and a solution to it has already been found or does not involve an inventive step having regard to to the state of the art as illustrated by:

a. US,A,4 943 628 (see in particular table 1).

b. WO,A1,87/07616 (see claims 1-6, fig 1 and page 9 lines 26-33)

Thus peptides from the region aa 150-300 of gp120 as well as mixtures of the peptides with other immunogenic peptides are known candidates for vaccine production.
Therefore, the original single general inventive concept is not acceptable anymore, making it necessary to reconsider the technical relationship between the different solutions mentioned.
This leads to their regrouping under distinct subjects as listed below, each subject now falling under its own inventive concept.

1. Claims 1-3,13,14,21 and 22 relate to a peptide GIKNCS.... ..QKEYAFF and homologs or analogs thereof and a vaccine composition comprising the peptide or mixtures comprising the peptide.

2. Claims 4-6, 15,16,21 and 22 relate to a peptide LTSCN.... ..PIHYC and homologs or analogs thereof and a vaccine compostition comprising the peptide or mixtures comprising the peptide.

3. Claims 7-9,17,18,21 and 22 relate to a peptide PKVSF.... ...LKCNN and homologs or analogs therof and a vaccine composition comprising the peptide or mixtures comprising the peptide.

4. Claims 10-12 and 19-22 relate to a peptide THSIR....SLAEEE and homologs or analogs thereof and a vaccine composition comprising the peptide or mixtures comprising the peptide.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00641

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 30/12/91 The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 8707616	87-12-17	AU-B-	617088	91-11-21
		AU-D-	7540487	88-01-11
		EP-A-	0269712	88-06-08
		JP-T-	1501547	89-06-01
		US-A-	5017688	91-05-21
		US-A-	4943627	90-07-24
WO-A1- 8910416	89-11-02	AU-D-	3557889	89-11-24
EP-A2- 0330359	89-08-30	AU-D-	3076189	89-08-31
		JP-A-	1308299	89-12-12
WO-A1- 8602383	86-04-24	AU-D-	5061785	86-05-02
		EP-A-B-	0201540	86-11-20
		EP-A-	0387914	90-09-19
		EP-A-	0387915	90-09-19
		EP-A-	0462627	91-12-27
		FR-A-B-	2571968	86-04-25
		JP-T-	62500592	87-03-12
		AU-B-	603543	90-11-22
		AU-B-	600227	90-08-09
		AU-D-	5320086	86-08-13
		EP-A-B-	0211022	87-02-25
		JP-T-	62502095	87-08-20
		OA-A-	8413	88-06-30
		WO-A-	86/04336	86-07-31
WO-A1- 8905820	89-06-29	WO-A-	89/05821	89-06-29
US-A- 4943628	90-07-24	NONE		
WO-A2- 9115512	91-10-17	NONE		
EP-A1- 0459779	91-12-04	NONE		
WO-A1- 9104045	91-04-04	NONE		